Skip to main content

Brant Allen Inman, MD, MS

Cary N. Robertson, MD, Associate Professor
Associate Professor of Surgery
Office: 3007 Snyderman Bldg, 905 La Salle Street, Durham, NC 27710
Campus Mail: DUMC DUMC Box 103868, Durham, NC 27710

Clinical research interests:
Clinical trials of novel diagnostic tests and therapies for genitourinary malignancies, with a strong focus on bladder cancer.

Basic science research interests:
Immune therapies for cancer, hyperthermia and heat-based treatment of cancer, molecular biology of genitourinary cancers, novel diagnostics and therapies for genitourinary cancers

Education and Training

  • Fellowship, Urologic Oncology, Mayo Clinic, 2005 - 2008
  • Residency, Urology, Universite Laval (Canada), 2001 - 2005
  • M.S., Mayo Medical School, 2011
  • M.D., University of Alberta (Canada), 2000
  • B.S., University of Alberta (Canada), 1999

Publications

Meleis, Laura, Russell Moore, Brant A. Inman, and Michael R. Harrison. “Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer..” J Oncol Pharm Pract, May 12, 2019. https://doi.org/10.1177/1078155219845434.

Full Text

Wang, Yingqi, Andrew Chang, Wei Phin Tan, Joseph Fantony, Gregory Barton, Paul Wischmeyer, Rajan Gupta, and Brant Inman. “INCREASING ADIPOSITY IN BLADDER CANCER SURVIVORS: DOES DIET MATTER?.” In Journal of Urology, 201:E47–E47. LIPPINCOTT WILLIAMS & WILKINS, 2019.

Scholars@Duke

Barton, Gregory John, Jeanette Wang, Andrew Chang, Wei Phin Tan, Joseph J. Fantony, Paul E. Wischmeyer, Rajan T. Gupta, and Brant Allen Inman. “Sarcopenia in bladder cancer patients is an unmodifiable outcomes predictor..” In Journal of Clinical Oncology, 37:480–480. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.480.

Full Text

Tan, Wei Phin, Gregory John Barton, Andrew Chang, Smita Nair, and Brant Allen Inman. “Sipuleucel-T to modify the B7-H3 immune checkpoint in men with castrate resistant prostate cancer..” In Journal of Clinical Oncology, 37:273–273. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.273.

Full Text

Dunkman, W Jonathan, Michael W. Manning, John Whittle, John Hunting, Edward N. Rampersaud, Brant A. Inman, Julie K. Thacker, and Timothy E. Miller. “Impact of an enhanced recovery pathway on length of stay and complications in elective radical cystectomy: a before and after cohort study..” Perioper Med (Lond) 8 (2019). https://doi.org/10.1186/s13741-019-0120-4.

Full Text

Soria, Francesco, Laura-Maria Krabbe, Tilman Todenhöfer, Jakub Dobruch, Anirban P. Mitra, Brant A. Inman, Kilian M. Gust, Yair Lotan, and Shahrokh F. Shariat. “Molecular markers in bladder cancer..” World J Urol 37, no. 1 (January 2019): 31–40. https://doi.org/10.1007/s00345-018-2503-4.

Full Text

Tan, W. P., W. S. Tan, and B. A. Inman. “PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis.” Bladder Cancer 5, no. 3 (January 1, 2019): 211–23. https://doi.org/10.3233/BLC-190238.

Full Text

Terlecki, R. P., N. L. Miller, and B. A. Inman. “Trends in Urological Referral Patterns: A Study of Community and University Urologists in the United States.” Urology Practice 5, no. 6 (November 1, 2018): 480–88. https://doi.org/10.1016/j.urpr.2017.11.003.

Full Text

Ingersoll, Molly A., Xue Li, Brant A. Inman, John W. Greiner, Peter C. Black, and Rosalyn M. Adam. “Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer..” Bladder Cancer (Amsterdam, Netherlands) 4, no. 4 (October 29, 2018): 429–40. https://doi.org/10.3233/BLC-180175.

Full Text

Pages